Skip to content
Screener

CapEx at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$16.08M+30.7%
ALN
Alnylam PharmaceuticalsALNY
$34.68M+143%
Assembly Biosciences logo
Assembly BiosciencesASMB
$19K
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$1M-66.7%
Beam Therapeutics logo
Beam TherapeuticsBEAM
$2.23M-27.2%
Dyne Therapeutics, Inc. logo
Dyne Therapeutics, Inc.DYN
$221K-77.5%

Other financials

Income statement

See full
Revenue$73.7M-86.4%
Operating income-$141.3M-137%
Net income-$132.7M-136%
EPS (diluted)-$0.93-134%

Balance sheet

See full
Cash & equivalents$188.5M+1.5%
Total debt$107.9M-5.6%
Total equity$614.0M-10.1%
Total assets$2.3B+44.2%

Cash flow

See full
Operating cash flow$84.4M-81.6%
Free cash flow$81.9M-82.0%

Valuation

See full
Market cap$12.28B+445%
Enterprise value$12.2B+446%
P/S19.7×+15.8×

Profitability

See full
Operating margin-35.7%+63.6pp
Net margin-48.4%+240pp
FCF margin1.8%+0.9pp

Returns & leverage

See full
Return on equity-46.4%+341pp
Debt / equity0.2×0.0×
Current ratio6.2×+1.1×

Where this comes from

Reported directly by Arrowhead Research in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

The source filing: Arrowhead Research’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:05 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q1 2026
Accession
0000879407-26-000047
Line itemSix Months Ended March 31, 2026Six Months Ended March 31, 2025
Other3613,169
Net cash provided by operating activities97,923313,781
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property, plant and equipment(4,713)(12,813)
Purchases of available-for-sale securities(1,061,577)(677,892)
Proceeds from sales of available-for-sale securities23,748
Proceeds from maturities of available-for-sale securities124,518347,402
Net cash used in investing activities(918,024)(343,303)

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Arrowhead Research's capex?
Arrowhead Research (ARWR) reported capex of $2.57M in Q1 2026.
How has Arrowhead Research's capex changed year-over-year?
Arrowhead Research's capex decreased by 51.6% year-over-year, from $5.3M to $2.57M.
What is the long-term trend for Arrowhead Research's capex?
Over 4 years (2021 to 2025), Arrowhead Research's capex has grown at a -1.0% compound annual growth rate (CAGR), from $23.57M to $22.67M.
What does capex mean?
Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.

Ask your AI about Arrowhead Research's capex.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude